KR20150048888A - 항콜린 신경보호 조성물 및 그 방법 - Google Patents

항콜린 신경보호 조성물 및 그 방법 Download PDF

Info

Publication number
KR20150048888A
KR20150048888A KR1020157008875A KR20157008875A KR20150048888A KR 20150048888 A KR20150048888 A KR 20150048888A KR 1020157008875 A KR1020157008875 A KR 1020157008875A KR 20157008875 A KR20157008875 A KR 20157008875A KR 20150048888 A KR20150048888 A KR 20150048888A
Authority
KR
South Korea
Prior art keywords
component
pharmaceutically acceptable
dose
hydrochloride
achei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157008875A
Other languages
English (en)
Korean (ko)
Inventor
캐슬린 이. 클라렌스-스미스
토마스 엔. 체이스
Original Assignee
체이스 파마슈티칼스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체이스 파마슈티칼스 코포레이션 filed Critical 체이스 파마슈티칼스 코포레이션
Publication of KR20150048888A publication Critical patent/KR20150048888A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020157008875A 2012-09-05 2013-09-05 항콜린 신경보호 조성물 및 그 방법 Ceased KR20150048888A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261697039P 2012-09-05 2012-09-05
US201261697021P 2012-09-05 2012-09-05
US201261696978P 2012-09-05 2012-09-05
US201261697069P 2012-09-05 2012-09-05
US61/696,978 2012-09-05
US61/697,039 2012-09-05
US61/697,069 2012-09-05
US61/697,021 2012-09-05
PCT/US2013/058172 WO2014039627A1 (en) 2012-09-05 2013-09-05 Anticholinergic neuroprotective composition and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015718A Division KR20200065113A (ko) 2012-09-05 2013-09-05 항콜린 신경보호 조성물 및 그 방법

Publications (1)

Publication Number Publication Date
KR20150048888A true KR20150048888A (ko) 2015-05-07

Family

ID=50237591

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157008875A Ceased KR20150048888A (ko) 2012-09-05 2013-09-05 항콜린 신경보호 조성물 및 그 방법
KR1020207015718A Ceased KR20200065113A (ko) 2012-09-05 2013-09-05 항콜린 신경보호 조성물 및 그 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207015718A Ceased KR20200065113A (ko) 2012-09-05 2013-09-05 항콜린 신경보호 조성물 및 그 방법

Country Status (14)

Country Link
US (4) US9561218B2 (https=)
EP (2) EP2892514A4 (https=)
JP (4) JP2015531346A (https=)
KR (2) KR20150048888A (https=)
CN (1) CN104768540A (https=)
AU (1) AU2013312749B2 (https=)
BR (3) BR112015004902A2 (https=)
CA (1) CA2882407C (https=)
EA (1) EA038489B1 (https=)
HK (1) HK1210947A1 (https=)
IL (3) IL237176B (https=)
IN (1) IN2015DN01706A (https=)
MX (2) MX385976B (https=)
WO (1) WO2014039627A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969402B2 (en) * 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
PT3061821T (pt) 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
AU2013300009B2 (en) * 2012-08-09 2017-06-15 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
BR112015004902A2 (pt) * 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
EP3242659A4 (en) * 2015-01-09 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system combination
US10596139B2 (en) 2015-03-06 2020-03-24 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
US10307409B2 (en) 2015-03-06 2019-06-04 Chase Pharmaceuticals Corporation Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
EP3347012A4 (en) * 2015-09-11 2019-04-17 Chase Pharmaceuticals Corporation MUSCARIN COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDER OF THE CENTRAL NERVOUS SYSTEM
CA2996717A1 (en) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US10357487B2 (en) * 2015-12-03 2019-07-23 Sidney J. Goldfarb Combinations of acetylcholinesterase inhibitors and muscarinic agonists and methods of use thereof
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
CA3071377C (en) 2017-01-09 2021-11-30 Kathleen E. Clarence-Smith Compositions and methods for improving muscle weakness in patients suffering from myasthenia gravis and other myasthenic syndromes
US20200000756A1 (en) * 2017-01-24 2020-01-02 Gt Biopharma, Inc. Neostigmine combination and compositions
IL269550B2 (en) 2017-03-27 2025-01-01 Chase Therapeutics Corp Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
US12112463B2 (en) 2020-09-14 2024-10-08 City University Of Hong Kong Method, device and computer readable medium for intrinsic popularity evaluation and content compression based thereon
US11759451B2 (en) 2020-09-15 2023-09-19 City University Of Hong Kong Therapeutic potential of glycopyrrolate and mexiletine for nervous system injury
US12109202B2 (en) * 2021-01-29 2024-10-08 Qaam Pharmaceuticals, Llc Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders
US20220304946A1 (en) * 2021-03-28 2022-09-29 Muhammad Imran Khan Trans-anethole ((e)-1-methoxy-4- (1-propenyl) benzene), a new and potent inhibitor of prolyl endopeptidase

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3480626A (en) 1967-05-18 1969-11-25 Chem Fab Dr R Pfleger Certain azoniaspironortropine derivatives
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
US3576388A (en) 1968-12-05 1971-04-27 Stauffer Wacker Silicone Corp Electrical cable
DD106643A1 (https=) 1973-07-12 1974-06-20
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB9423588D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
AU749088C (en) 1997-07-09 2005-11-03 Axonyx, Inc. Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
EP0976404A3 (en) 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
EP1121104B1 (en) 1998-10-01 2005-01-12 Novartis AG New controlled release oral formulations for rivastigmine
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU2002253929A1 (en) 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US7427280B2 (en) 2002-09-06 2008-09-23 Medtronic, Inc. Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues
CN1520818A (zh) 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
DE602005016775D1 (de) 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
AR051950A1 (es) 2004-11-10 2007-02-21 Osmotica Pharmaceutical Argent Comprimido multicapa con capas que se separan
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
US7390816B2 (en) 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20070224259A1 (en) 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
US20070093519A1 (en) * 2005-10-20 2007-04-26 Indevus Pharmaceuticals, Inc. Anti-emetic uses of cannabinoid analogs
US20070099988A1 (en) * 2005-10-31 2007-05-03 Indevus Pharmaceuticals, Inc. Anti-emetic uses of (3r, 4r)-delta8-tetrahydrocannabinol-11-oic acids
EP1879867A2 (en) 2005-12-21 2008-01-23 Teva Pharmaceutical Industries Ltd Intermediates for preparing solifenacin
CN101472877A (zh) 2006-04-21 2009-07-01 惠氏公司 制备手性纯氨基醇中间体、其衍生物及其用途
EP2295045A1 (en) 2006-07-07 2011-03-16 Aarhus Universitet Nanoparticles for nucleic acid delivery
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2011034568A1 (en) 2009-09-18 2011-03-24 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
WO2009139002A2 (en) 2008-05-12 2009-11-19 Msn Laboratories Limited An improved process for the preparation of solifenacin and its pharmaceutically acceptable salts thereof
SI2451809T1 (sl) 2009-07-09 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo in čiščenje soli solifenacina
EP2470504B1 (en) 2010-03-15 2013-10-16 Ramesha Andagar Ramakrishna Synthesis of propiverine hydrochloride
US8729056B2 (en) * 2010-03-31 2014-05-20 Ono Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of hand-foot syndrome
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
BR112015004902A2 (pt) * 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos

Also Published As

Publication number Publication date
HK1210947A1 (en) 2016-05-13
CN104768540A (zh) 2015-07-08
MX2020002113A (es) 2021-09-08
IL237176B (en) 2018-02-28
IL257150A (en) 2018-03-29
AU2013312749A1 (en) 2015-04-02
US20190000826A1 (en) 2019-01-03
BR122016020434A2 (pt) 2019-08-27
CA2882407A1 (en) 2014-03-13
MX378091B (es) 2025-03-10
US20150231122A1 (en) 2015-08-20
IL268603B (en) 2021-03-25
EP4035668A1 (en) 2022-08-03
JP2018150314A (ja) 2018-09-27
EA201500293A1 (ru) 2015-07-30
EP2892514A1 (en) 2015-07-15
BR122016020433A2 (pt) 2019-08-27
CA2882407C (en) 2022-11-15
IN2015DN01706A (https=) 2015-05-22
US9561218B2 (en) 2017-02-07
AU2013312749B2 (en) 2018-01-18
US9913836B2 (en) 2018-03-13
EP2892514A4 (en) 2016-04-13
MX2015002864A (es) 2015-07-14
JP2021191759A (ja) 2021-12-16
US20190365736A1 (en) 2019-12-05
EA038489B1 (ru) 2021-09-06
KR20200065113A (ko) 2020-06-08
IL237176A0 (en) 2015-04-30
IL268603A (en) 2019-10-31
WO2014039627A1 (en) 2014-03-13
MX385976B (es) 2025-03-18
JP2020105212A (ja) 2020-07-09
BR112015004902A2 (pt) 2017-07-04
US20170087142A1 (en) 2017-03-30
JP2015531346A (ja) 2015-11-02
AU2013312749A2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
KR20150048888A (ko) 항콜린 신경보호 조성물 및 그 방법
JP6427522B2 (ja) 認知症を治療するための使用及び組成物
US9943508B2 (en) Method and composition for treating Alzheimer-type dementia
AU2022246374A1 (en) Method and composition for treating Alzheimer-type dementia
AU2016231489B2 (en) Composition for treating dementia
HK1239557A1 (en) Combination of a nspacha (peripheral anticholinergic agent) like solifenacin and an achei (acetyl choline esterase inhibitor) like donepezil for treating dementia
AU2014277685A1 (en) Composition for treating dementia
AU2016231493A2 (en) Composition for treating dementia

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150406

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180905

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200128

Patent event code: PE09021S01D

AMND Amendment
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200601

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201019

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200128

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201019

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200531

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180905

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150407

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210127

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210118

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20201019

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200531

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200128

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180905

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20150407

X601 Decision of rejection after re-examination